Craig Thompson, CEO of Cerevance touches on the NETSseq platform and how it shapes Cerevance's approach to the drug discovery strategy.

Details of the agreement are confidential, but it reportedly fulfills the requirements President Trump set forth in a July ...

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to ...

Kedrion Biopharma celebrates FDA approval of Qivigy, enhancing treatment options for primary immunodeficiency while ...

Novo Nordisk aims to revolutionize diabetes care with Awiqli, a potential once-weekly insulin, resubmitted for FDA approval ...

Craig Thompson, CEO of Cerevance discusses the key scientific and clinical insights that lead to Cerevance's pursuit of Solengepras.

The MFN executive order may result in the US losing its place as the friendliest market for innovation.

AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK. Enhertu shows superior outcomes in early-stage ...

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s ...

AbbVie officially began construction on its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, ...

Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like ...

GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.